Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study Meeting Abstract
| Authors: | Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; Melichar, B.; Siena, S.; Stroyakovskiy, D.; Fielding, A.; Ma, Y.; Puvvada, S. D.; Lee, J. Y. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1273 |
| End Page: | S1274 |
| Language: | English |
| ACCESSION: | WOS:001087480203513 |
| DOI: | 10.1016/j.annonc.2023.10.026 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA34 -- Source: Wos |
